Showing results (501-510 of 744) with videos related to

Sort By:
Pageof 75
Molecular Cancer Therapeutics|June 19, 2007
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structureRobert W Robey, Suneet Shukla, Kenneth Steadman, et al.
Seminars in Oncology|August 1, 2022
Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNAAshray Maniar, Alexander Z Wei, Laurent Dercle, et al.
Nature Reviews. Cancer|April 13, 2018
Revisiting the role of ABC transporters in multidrug-resistant cancerRobert W Robey, Kristen M Pluchino, Matthew D Hall, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2004
ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecinsSusan E Bates, Wilma Y Medina-Pérez, Glenda Kohlhagen, et al.
Clinical Journal of Oncology Nursing|March 31, 2012
Romidepsin: a new drug for the treatment of cutaneous T-cell lymphomaRobin Frye, Mary Myers, Karen C Axelrod, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinomaWilfred D Stein, Hui Huang, Michael Menefee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2017
Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma"Erkut Borazanci, Chi V Dang, Robert W Robey, et al.
Cell Cycle (Georgetown, Tex.)|April 21, 2010
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cellsJyoti Panicker, Zhijie Li, Christine McMahon, et al.
Seminars in Oncology|June 5, 2021
Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrualGrace Clarke Hillyer, Yeun-Hee Anna Park, Ta-Chueh Hsu Rosenberg, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 28, 2009
Association between plasma 25-hydroxyvitamin D and breast cancer riskKatherine D Crew, Marilie D Gammon, Susan E Steck, et al.
Pageof 75